Global Blood Plasma Fractionation Market Analysis and Forecast 2025-2031

Summary

According to APO Research, The global Blood Plasma Fractionation market is projected to grow from US$ million in 2025 to US$ million by 2031, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Blood Plasma Fractionation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Asia-Pacific market for Blood Plasma Fractionation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The China market for Blood Plasma Fractionation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

Europe market for Blood Plasma Fractionation is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.

The major global companies of Blood Plasma Fractionation include Biotest, BPL, CSL, Grifols, Kedrion, KM Biologics, LFB Group, Octapharma and Takeda, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Blood Plasma Fractionation, market size. Analyses of the global market trends, with historic market revenue data for 2020 - 2024, estimates for 2025, and projections of CAGR through 2031.

This report researches the key producers of Blood Plasma Fractionation, also provides the revenue of main regions and countries. Of the upcoming market potential for Blood Plasma Fractionation, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Blood Plasma Fractionation revenue, market share and industry ranking of main manufacturers, data from 2020 to 2025. Identification of the major stakeholders in the global Blood Plasma Fractionation market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2020 to 2031. Evaluation and forecast the market size for Blood Plasma Fractionation revenue, projected growth trends, production technology, application and end-user industry.

Blood Plasma Fractionation Segment by Company

Biotest
BPL
CSL
Grifols
Kedrion
KM Biologics
LFB Group
Octapharma
Takeda
Boya Bio
Hualan Bio
Nanyue Bio
RAAS
Shuanglin Bio
CBPO
Tiantan Bio
Weiguang Bio
Yuanda Shuyang
Blood Plasma Fractionation Segment by Type

Coagulation Factor
Immune Globulin
Albumin
Other
Blood Plasma Fractionation Segment by Application

Hospital
Retail Pharmacy
Other
Blood Plasma Fractionation Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Spain
Netherlands
Switzerland
Sweden
Poland
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Egypt
South Africa
Israel
Türkiye
GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.
2. To present the key players, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Blood Plasma Fractionation market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Blood Plasma Fractionation and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Blood Plasma Fractionation.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Revenue of Blood Plasma Fractionation in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 4: Detailed analysis of Blood Plasma Fractionation company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Blood Plasma Fractionation revenue, gross margin, and recent development, etc.
Chapter 8: North America by type, by application and by country, revenue for each segment.
Chapter 9: Europe by type, by application and by country, revenue for each segment.
Chapter 10: China type, by application, revenue for each segment.
Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.
Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.
Chapter 13: The main concluding insights of the report.

Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.


1 Market Overview
1.1 Product Definition
1.2 Blood Plasma Fractionation Market by Type
1.2.1 Global Blood Plasma Fractionation Market Size by Type, 2020 VS 2024 VS 2031
1.2.2 Coagulation Factor
1.2.3 Immune Globulin
1.2.4 Albumin
1.2.5 Other
1.3 Blood Plasma Fractionation Market by Application
1.3.1 Global Blood Plasma Fractionation Market Size by Application, 2020 VS 2024 VS 2031
1.3.2 Hospital
1.3.3 Retail Pharmacy
1.3.4 Other
1.4 Assumptions and Limitations
1.5 Study Goals and Objectives
2 Blood Plasma Fractionation Market Dynamics
2.1 Blood Plasma Fractionation Industry Trends
2.2 Blood Plasma Fractionation Industry Drivers
2.3 Blood Plasma Fractionation Industry Opportunities and Challenges
2.4 Blood Plasma Fractionation Industry Restraints
3 Global Growth Perspective
3.1 Global Blood Plasma Fractionation Market Perspective (2020-2031)
3.2 Global Blood Plasma Fractionation Growth Trends by Region
3.2.1 Global Blood Plasma Fractionation Market Size by Region: 2020 VS 2024 VS 2031
3.2.2 Global Blood Plasma Fractionation Market Size by Region (2020-2025)
3.2.3 Global Blood Plasma Fractionation Market Size by Region (2026-2031)
4 Competitive Landscape by Players
4.1 Global Blood Plasma Fractionation Revenue by Players
4.1.1 Global Blood Plasma Fractionation Revenue by Players (2020-2025)
4.1.2 Global Blood Plasma Fractionation Revenue Market Share by Players (2020-2025)
4.1.3 Global Blood Plasma Fractionation Players Revenue Share Top 10 and Top 5 in 2024
4.2 Global Blood Plasma Fractionation Key Players Ranking, 2023 VS 2024 VS 2025
4.3 Global Blood Plasma Fractionation Key Players Headquarters & Area Served
4.4 Global Blood Plasma Fractionation Players, Product Type & Application
4.5 Global Blood Plasma Fractionation Players Establishment Date
4.6 Market Competitive Analysis
4.6.1 Global Blood Plasma Fractionation Market CR5 and HHI
4.6.3 2024 Blood Plasma Fractionation Tier 1, Tier 2, and Tier 3
5 Blood Plasma Fractionation Market Size by Type
5.1 Global Blood Plasma Fractionation Revenue by Type (2020 VS 2024 VS 2031)
5.2 Global Blood Plasma Fractionation Revenue by Type (2020-2031)
5.3 Global Blood Plasma Fractionation Revenue Market Share by Type (2020-2031)
6 Blood Plasma Fractionation Market Size by Application
6.1 Global Blood Plasma Fractionation Revenue by Application (2020 VS 2024 VS 2031)
6.2 Global Blood Plasma Fractionation Revenue by Application (2020-2031)
6.3 Global Blood Plasma Fractionation Revenue Market Share by Application (2020-2031)
7 Company Profiles
7.1 Biotest
7.1.1 Biotest Comapny Information
7.1.2 Biotest Business Overview
7.1.3 Biotest Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.1.4 Biotest Blood Plasma Fractionation Product Portfolio
7.1.5 Biotest Recent Developments
7.2 BPL
7.2.1 BPL Comapny Information
7.2.2 BPL Business Overview
7.2.3 BPL Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.2.4 BPL Blood Plasma Fractionation Product Portfolio
7.2.5 BPL Recent Developments
7.3 CSL
7.3.1 CSL Comapny Information
7.3.2 CSL Business Overview
7.3.3 CSL Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.3.4 CSL Blood Plasma Fractionation Product Portfolio
7.3.5 CSL Recent Developments
7.4 Grifols
7.4.1 Grifols Comapny Information
7.4.2 Grifols Business Overview
7.4.3 Grifols Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.4.4 Grifols Blood Plasma Fractionation Product Portfolio
7.4.5 Grifols Recent Developments
7.5 Kedrion
7.5.1 Kedrion Comapny Information
7.5.2 Kedrion Business Overview
7.5.3 Kedrion Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.5.4 Kedrion Blood Plasma Fractionation Product Portfolio
7.5.5 Kedrion Recent Developments
7.6 KM Biologics
7.6.1 KM Biologics Comapny Information
7.6.2 KM Biologics Business Overview
7.6.3 KM Biologics Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.6.4 KM Biologics Blood Plasma Fractionation Product Portfolio
7.6.5 KM Biologics Recent Developments
7.7 LFB Group
7.7.1 LFB Group Comapny Information
7.7.2 LFB Group Business Overview
7.7.3 LFB Group Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.7.4 LFB Group Blood Plasma Fractionation Product Portfolio
7.7.5 LFB Group Recent Developments
7.8 Octapharma
7.8.1 Octapharma Comapny Information
7.8.2 Octapharma Business Overview
7.8.3 Octapharma Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.8.4 Octapharma Blood Plasma Fractionation Product Portfolio
7.8.5 Octapharma Recent Developments
7.9 Takeda
7.9.1 Takeda Comapny Information
7.9.2 Takeda Business Overview
7.9.3 Takeda Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.9.4 Takeda Blood Plasma Fractionation Product Portfolio
7.9.5 Takeda Recent Developments
7.10 Boya Bio
7.10.1 Boya Bio Comapny Information
7.10.2 Boya Bio Business Overview
7.10.3 Boya Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.10.4 Boya Bio Blood Plasma Fractionation Product Portfolio
7.10.5 Boya Bio Recent Developments
7.11 Hualan Bio
7.11.1 Hualan Bio Comapny Information
7.11.2 Hualan Bio Business Overview
7.11.3 Hualan Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.11.4 Hualan Bio Blood Plasma Fractionation Product Portfolio
7.11.5 Hualan Bio Recent Developments
7.12 Nanyue Bio
7.12.1 Nanyue Bio Comapny Information
7.12.2 Nanyue Bio Business Overview
7.12.3 Nanyue Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.12.4 Nanyue Bio Blood Plasma Fractionation Product Portfolio
7.12.5 Nanyue Bio Recent Developments
7.13 RAAS
7.13.1 RAAS Comapny Information
7.13.2 RAAS Business Overview
7.13.3 RAAS Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.13.4 RAAS Blood Plasma Fractionation Product Portfolio
7.13.5 RAAS Recent Developments
7.14 Shuanglin Bio
7.14.1 Shuanglin Bio Comapny Information
7.14.2 Shuanglin Bio Business Overview
7.14.3 Shuanglin Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.14.4 Shuanglin Bio Blood Plasma Fractionation Product Portfolio
7.14.5 Shuanglin Bio Recent Developments
7.15 CBPO
7.15.1 CBPO Comapny Information
7.15.2 CBPO Business Overview
7.15.3 CBPO Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.15.4 CBPO Blood Plasma Fractionation Product Portfolio
7.15.5 CBPO Recent Developments
7.16 Tiantan Bio
7.16.1 Tiantan Bio Comapny Information
7.16.2 Tiantan Bio Business Overview
7.16.3 Tiantan Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.16.4 Tiantan Bio Blood Plasma Fractionation Product Portfolio
7.16.5 Tiantan Bio Recent Developments
7.17 Weiguang Bio
7.17.1 Weiguang Bio Comapny Information
7.17.2 Weiguang Bio Business Overview
7.17.3 Weiguang Bio Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.17.4 Weiguang Bio Blood Plasma Fractionation Product Portfolio
7.17.5 Weiguang Bio Recent Developments
7.18 Yuanda Shuyang
7.18.1 Yuanda Shuyang Comapny Information
7.18.2 Yuanda Shuyang Business Overview
7.18.3 Yuanda Shuyang Blood Plasma Fractionation Revenue and Gross Margin (2020-2025)
7.18.4 Yuanda Shuyang Blood Plasma Fractionation Product Portfolio
7.18.5 Yuanda Shuyang Recent Developments
8 North America
8.1 North America Blood Plasma Fractionation Revenue (2020-2031)
8.2 North America Blood Plasma Fractionation Revenue by Type (2020-2031)
8.2.1 North America Blood Plasma Fractionation Revenue by Type (2020-2025)
8.2.2 North America Blood Plasma Fractionation Revenue by Type (2026-2031)
8.3 North America Blood Plasma Fractionation Revenue Share by Type (2020-2031)
8.4 North America Blood Plasma Fractionation Revenue by Application (2020-2031)
8.4.1 North America Blood Plasma Fractionation Revenue by Application (2020-2025)
8.4.2 North America Blood Plasma Fractionation Revenue by Application (2026-2031)
8.5 North America Blood Plasma Fractionation Revenue Share by Application (2020-2031)
8.6 North America Blood Plasma Fractionation Revenue by Country
8.6.1 North America Blood Plasma Fractionation Revenue by Country (2020 VS 2024 VS 2031)
8.6.2 North America Blood Plasma Fractionation Revenue by Country (2020-2025)
8.6.3 North America Blood Plasma Fractionation Revenue by Country (2026-2031)
8.6.4 United States
8.6.5 Canada
8.6.6 Mexico
9 Europe
9.1 Europe Blood Plasma Fractionation Revenue (2020-2031)
9.2 Europe Blood Plasma Fractionation Revenue by Type (2020-2031)
9.2.1 Europe Blood Plasma Fractionation Revenue by Type (2020-2025)
9.2.2 Europe Blood Plasma Fractionation Revenue by Type (2026-2031)
9.3 Europe Blood Plasma Fractionation Revenue Share by Type (2020-2031)
9.4 Europe Blood Plasma Fractionation Revenue by Application (2020-2031)
9.4.1 Europe Blood Plasma Fractionation Revenue by Application (2020-2025)
9.4.2 Europe Blood Plasma Fractionation Revenue by Application (2026-2031)
9.5 Europe Blood Plasma Fractionation Revenue Share by Application (2020-2031)
9.6 Europe Blood Plasma Fractionation Revenue by Country
9.6.1 Europe Blood Plasma Fractionation Revenue by Country (2020 VS 2024 VS 2031)
9.6.2 Europe Blood Plasma Fractionation Revenue by Country (2020-2025)
9.6.3 Europe Blood Plasma Fractionation Revenue by Country (2026-2031)
9.6.4 Germany
9.6.5 France
9.6.6 U.K.
9.6.7 Italy
9.6.8 Russia
9.6.9 Spain
9.6.10 Netherlands
9.6.11 Switzerland
9.6.12 Sweden
9.6.13 Poland
10 China
10.1 China Blood Plasma Fractionation Revenue (2020-2031)
10.2 China Blood Plasma Fractionation Revenue by Type (2020-2031)
10.2.1 China Blood Plasma Fractionation Revenue by Type (2020-2025)
10.2.2 China Blood Plasma Fractionation Revenue by Type (2026-2031)
10.3 China Blood Plasma Fractionation Revenue Share by Type (2020-2031)
10.4 China Blood Plasma Fractionation Revenue by Application (2020-2031)
10.4.1 China Blood Plasma Fractionation Revenue by Application (2020-2025)
10.4.2 China Blood Plasma Fractionation Revenue by Application (2026-2031)
10.5 China Blood Plasma Fractionation Revenue Share by Application (2020-2031)
11 Asia (Excluding China)
11.1 Asia Blood Plasma Fractionation Revenue (2020-2031)
11.2 Asia Blood Plasma Fractionation Revenue by Type (2020-2031)
11.2.1 Asia Blood Plasma Fractionation Revenue by Type (2020-2025)
11.2.2 Asia Blood Plasma Fractionation Revenue by Type (2026-2031)
11.3 Asia Blood Plasma Fractionation Revenue Share by Type (2020-2031)
11.4 Asia Blood Plasma Fractionation Revenue by Application (2020-2031)
11.4.1 Asia Blood Plasma Fractionation Revenue by Application (2020-2025)
11.4.2 Asia Blood Plasma Fractionation Revenue by Application (2026-2031)
11.5 Asia Blood Plasma Fractionation Revenue Share by Application (2020-2031)
11.6 Asia Blood Plasma Fractionation Revenue by Country
11.6.1 Asia Blood Plasma Fractionation Revenue by Country (2020 VS 2024 VS 2031)
11.6.2 Asia Blood Plasma Fractionation Revenue by Country (2020-2025)
11.6.3 Asia Blood Plasma Fractionation Revenue by Country (2026-2031)
11.6.4 Japan
11.6.5 South Korea
11.6.6 India
11.6.7 Australia
11.6.8 Taiwan
11.6.9 Southeast Asia
12 South America, Middle East and Africa
12.1 SAMEA Blood Plasma Fractionation Revenue (2020-2031)
12.2 SAMEA Blood Plasma Fractionation Revenue by Type (2020-2031)
12.2.1 SAMEA Blood Plasma Fractionation Revenue by Type (2020-2025)
12.2.2 SAMEA Blood Plasma Fractionation Revenue by Type (2026-2031)
12.3 SAMEA Blood Plasma Fractionation Revenue Share by Type (2020-2031)
12.4 SAMEA Blood Plasma Fractionation Revenue by Application (2020-2031)
12.4.1 SAMEA Blood Plasma Fractionation Revenue by Application (2020-2025)
12.4.2 SAMEA Blood Plasma Fractionation Revenue by Application (2026-2031)
12.5 SAMEA Blood Plasma Fractionation Revenue Share by Application (2020-2031)
12.6 SAMEA Blood Plasma Fractionation Revenue by Country
12.6.1 SAMEA Blood Plasma Fractionation Revenue by Country (2020 VS 2024 VS 2031)
12.6.2 SAMEA Blood Plasma Fractionation Revenue by Country (2020-2025)
12.6.3 SAMEA Blood Plasma Fractionation Revenue by Country (2026-2031)
12.6.4 Brazil
12.6.5 Argentina
12.6.6 Chile
12.6.7 Colombia
12.6.8 Peru
12.6.9 Saudi Arabia
12.6.10 Israel
12.6.11 UAE
12.6.12 Turkey
12.6.13 Iran
12.6.14 Egypt
13 Concluding Insights
14 Appendix
14.1 Reasons for Doing This Study
14.2 Research Methodology
14.3 Research Process
14.4 Authors List of This Report
14.5 Data Source
14.5.1 Secondary Sources
14.5.2 Primary Sources
14.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings